Stephens Inc’s Ocular Therapeutix OCUL Stock Holding History

Stephens Inc’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-22,500	Closed	-$111K	–	1185
2020 Q1	$111K	Buy	+22,500	New	+$111K	﹤0.01%	967

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Inc's OCUL Position: Q2 2020 in Review

Stephens Inc sold out of Ocular Therapeutix (OCUL) in Q2 2020, closing a stake of 22,500 shares — an estimated $111K sold.

Stephens Inc first reported a position in OCUL in Q1 2020 and held it in 1 quarter. The position peaked at $111K in Q1 2020. 106 funds tracked by Wall St. Rank hold OCUL as of Q2 2020.

Stephens Inc reported no remaining Ocular Therapeutix position as of Q2 2020 after selling out during the quarter.
Stephens Inc sold 22,500 Ocular Therapeutix shares in Q2 2020, an estimated $111K.
Stephens Inc first reported a position in Ocular Therapeutix in Q1 2020 and held it in 1 quarter.
Stephens Inc's Ocular Therapeutix position peaked at $111K in Q1 2020.
106 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2020.

Based on Stephens Inc's 13F filing for Q2 2020, filed 24 Aug 2020.